Cite
Nakamura K, Nishida T, Haruma T, et al. Pretreatment platelet-lymphocyte ratio is an independent predictor of cervical cancer recurrence following concurrent chemoradiation therapy. Mol Clin Oncol. 2015;3(5):1001-1006doi: 10.3892/mco.2015.595.
Nakamura, K., Nishida, T., Haruma, T., Haraga, J., Omichi, C., Ogawa, C., Kusumoto, T., Seki, N., Masuyama, H., & Hiramatsu, Y. (2015). Pretreatment platelet-lymphocyte ratio is an independent predictor of cervical cancer recurrence following concurrent chemoradiation therapy. Molecular and clinical oncology, 3(5), 1001-1006. https://doi.org/10.3892/mco.2015.595
Nakamura, Keiichiro, et al. "Pretreatment platelet-lymphocyte ratio is an independent predictor of cervical cancer recurrence following concurrent chemoradiation therapy." Molecular and clinical oncology vol. 3,5 (2015): 1001-1006. doi: https://doi.org/10.3892/mco.2015.595
Nakamura K, Nishida T, Haruma T, Haraga J, Omichi C, Ogawa C, Kusumoto T, Seki N, Masuyama H, Hiramatsu Y. Pretreatment platelet-lymphocyte ratio is an independent predictor of cervical cancer recurrence following concurrent chemoradiation therapy. Mol Clin Oncol. 2015 Sep;3(5):1001-1006. doi: 10.3892/mco.2015.595. Epub 2015 Jul 01. PMID: 26623040; PMCID: PMC4535152.
Copy
Download .nbib